On Oct 15, major Wall Street analysts update their ratings for $Intuitive Surgical (ISRG.US)$, with price targets ranging from $500 to $570.
Mizuho Securities analyst Anthony Petrone maintains with a hold rating, and adjusts the target price from $390 to $500.
BTIG analyst Ryan Zimmerman maintains with a buy rating, and adjusts the target price from $494 to $518.
Raymond James analyst Jayson Bedford maintains with a buy rating, and adjusts the target price from $310 to $540.
Truist Financial analyst Richard Newitter maintains with a buy rating, and adjusts the target price from $520 to $570.
Furthermore, according to the comprehensive report, the opinions of $Intuitive Surgical (ISRG.US)$'s main analysts recently are as follows:
The MedTech sector experienced 'solid returns' with Providers standing out within healthcare sub-sectors, exemplified by a 10.5% performance for the iShares U.S. Healthcare Providers ETF (IHF). This trend corresponds with the fundamental feedback from Q3, indicating that procedure volumes remain robust and demand continues to be strong. Further insights gathered from various sub-sectors suggest that the current demand for procedures is expected to persist into 2025, bolstered by demographic factors and sustained low unemployment levels.
Here are the latest investment ratings and price targets for $Intuitive Surgical (ISRG.US)$ from 4 analysts:
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
美東時間10月15日，多家華爾街大行更新了$直覺外科公司 (ISRG.US)$的評級，目標價介於500美元至570美元。
瑞穗證券分析師Anthony Petrone維持持有評級，並將目標價從390美元上調至500美元。
BTIG分析師Ryan Zimmerman維持買入評級，並將目標價從494美元上調至518美元。
瑞傑金融分析師Jayson Bedford維持買入評級，並將目標價從310美元上調至540美元。
儲億銀行分析師Richard Newitter維持買入評級，並將目標價從520美元上調至570美元。
此外，綜合報道，$直覺外科公司 (ISRG.US)$近期主要分析師觀點如下：
以下爲今日4位分析師對$直覺外科公司 (ISRG.US)$的最新投資評級及目標價：
提示:
TipRanks為獨立第三方，提供金融分析師的分析數據，並計算分析師推薦的平均回報率和勝率。提供的信息並非投資建議，僅供参考。本文不對評級數據和報告的完整性與準確性做出認可、聲明或保證。
TipRanks提供每位分析師的星級，分析師星級代表分析師所有推薦的過往表現，通過分析師的總勝率和平均回報率综合計算得出，星星越多，則該分析師過往表現越優異，最高爲5颗星。
分析師總勝率為近一年分析師的評級成功次數占總評級次數的比率。評级的成功與否，取決於TipRanks的虚擬投資組合是否從該股票中產生正回報。
總平均回報率為基於分析師的初始評級創建虚擬投資組合，並根據評級變化對組合進行調整，在近一年中該投資組合所獲得的回報率。
